Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

about

Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.Non-alcoholic fatty liver and the gut microbiota.Impact of etiological treatment on prognosis.Managing the Burden of Non-NASH NAFLD.Non-alcoholic fatty liver disease

P2860

Q30235846-069A90C6-46AE-4861-8F4D-AE38E3AC3D33 Q37215934-28EA4801-D3D5-49B2-8D97-8D510DD9CCF0 Q39431994-2CFA5C90-B764-46B4-88B3-EE0D96E2953A Q53704720-D3D1FEBA-35DC-4EFF-A303-1216631466D1 Q56003593-73780563-0BD5-4283-AA3C-1458C3E63FA7

P2860

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

Item

http://www.wikidata.org/entity/Q36818351

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

@ast

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

@en

type

Item

label

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

@ast

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

@en

prefLabel

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

@ast

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

@en

P1476

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis

@en

P2093

Mary E Rinella

http://www.w3.org/2001/XMLSchema#string

P2860

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Fructose consumption as a risk factor for non-alcoholic fatty liver disease

Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Intermediary metabolism of fructose

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

P2888

s10620-016-4083-8

P304

1387-1397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-016-4083-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kathleen E Corey

P577

2016-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26942734

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

4838504

http://www.w3.org/2001/XMLSchema#string

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

about

P2860

P2860

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932